China NT Pharma Group Company Limited provided earnings guidance for the six months ended June 30, 2013. The Board currently estimates that the Group will likely record a loss for the six months ended June 30, 2013. The loss is mainly attributed to the Group's business restructuring measures introduced in 2012 which involved the exiting from its vaccine and pharmaceutical supply chain business, the downsizing of its vaccine sales and promotion team as well as the termination of its over-the-counter promotion business and several dermatological products.

As a result, the Group may incur further impairment charges for account receivables and inventories in relation to the terminated businesses, which will likely lead to a loss for the six months ended June 30, 2013.